• ???This agreement, our second for DX-88 in less than a year, highlights the significant value and broad therapeutic potential of this important and versatile product,??? commented Gustav A. Christensen, President and Chief Executive Officer of Dyax Corp. ???The Ophthalmic pharmaceutical market is a rapidly growing field and Fovea is an innovative participant dedicated to its advancement.